Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer

We performed a meta-analysis to comprehensively investigate the efficacy and safety of immune-checkpoint inhibitors (ICIs) plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). The primary outcome was overall survival (OS). The secondary outcomes included progression-f...

Full description

Saved in:

Bibliographic Details
Main Authors:	Caicun Zhou, Tao Jiang, Fei Zhou, Wencheng Zhao, Xiaomei Gong, Shengxiang Ren, Chunxia Su
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-10-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/8/2/e001300.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
by: Caicong You, et al.
Published: (2024-12-01)

Adding checkpoint inhibitors to first-line chemotherapy for NUT carcinoma patients
by: Sarah Haebe, et al.
Published: (2025-01-01)

Safety and efficacy of Immune checkpoint Inhibitors (ICIs) plus chemotherapy versus chemotherapy alone for small cell lung cancer (SCLC): A systematic review and meta-analysis of randomized controlled trials
by: Xiaohong Mu, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
by: Wenwang Lang, et al.
Published: (2024-11-01)

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence
by: Yuta Yamanaka, et al.
Published: (2024-12-01)

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors
by: Lucillia Bezu, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

Comparative efficacy and safety of anti-HGF/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis
by: Chunyu Liu, et al.
Published: (2021-12-01)

Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
by: Sara Kaveh, et al.
Published: (2024-11-01)

First-line chemotherapy with tislelizumab for patients with extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Rong Long, et al.
Published: (2024-12-01)

PD-L1 as a response biomarker to chemotherapy plus immune checkpoint inhibitors in operable gastroesophageal adenocarcinoma: a meta-analysis of neoadjuvant clinical trials
by: A. Cammarota, et al.
Published: (2024-12-01)

Anlotinib as Maintenance Therapy After First-Line Chemotherapy Combined with Consolidation Radiation for Extensive-Stage Small Cell Lung Cancer
by: Jinbo Ma MD, et al.
Published: (2025-01-01)

Impact of DLL3 Expression as Prognostic Factor in Extensive Stage of Small Cell Lung Cancer Treated With First‐Line Chemotherapy
by: Hohyung Nam, et al.
Published: (2025-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Prognostic value of the lactate dehydrogenase to albumin ratio in advanced non-small cell lung cancer patients treated with the first-line PD-1 checkpoint inhibitors combined with chemotherapy
by: Meifeng Luo, et al.
Published: (2025-02-01)

Preoperative immunochemotherapy versus chemotherapy as first-line treatment for patients with stage I–IIIB small-cell lung cancer
by: Linhai Zhu, et al.
Published: (2025-01-01)

A multicenter retrospective study of the combination of immune checkpoint inhibitors and chemotherapy regimens with or without liver metastasis for the first-line treatment of advanced gastric cancer
by: Jing Ren, et al.
Published: (2024-12-01)

CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
by: Zhao Yang, et al.
Published: (2020-10-01)

Effect of trilaciclib administered before chemotherapy in patients with extensive-stage small-cell lung cancer: A pooled analysis of four randomized studies
by: Ying Liu, et al.
Published: (2024-01-01)

Efficacy of first-line radiofrequency ablation combined with systemic chemotherapy plus targeted therapy for initially unresectable colorectal liver metastases
by: Yaqing Kong, et al.
Published: (2025-12-01)

Immune Checkpoint Inhibitors +/− Chemotherapy for Patients With NSCLC and Brain Metastases: A Systematic Review and Network Meta‐Analysis
by: Lauren Julia Brown, et al.
Published: (2025-01-01)

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy
by: Chiara Bini, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of benmelstobart, anlotinib, and chemotherapy in extensive-stage small-cell lung cancer
by: Maojin You, et al.
Published: (2024-11-01)

Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

Feasibility and predictive factors on the completion of docetaxel plus S‐1 adjuvant chemotherapy in pathological stage III gastric cancer
by: Masayoshi Terayama, et al.
Published: (2025-01-01)

Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab
by: Masatsune Shibutani, et al.
Published: (2025-01-01)

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
by: Jun Lu, et al.
Published: (2024-04-01)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
by: Songporn Oranratnachai, et al.
Published: (2023-02-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
by: Marlise R. Luskin, et al.
Published: (2025-02-01)

Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration
by: Du Feng, et al.
Published: (2024-12-01)

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
by: Nobuyuki Yamamoto, et al.
Published: (2020-05-01)

Anlotinib plus chemotherapy as a first-line treatment for gastrointestinal cancer patients with unresectable liver metastases: a multicohort, multicenter, exploratory trial
by: Jun-Wei Wu, et al.
Published: (2024-12-01)

Genetic Variations Affect Chemotherapy Outcomes: A Role of the Spindle-assembly Checkpoint
by: Sinjini Sarkar, et al.
Published: (2024-04-01)

Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy—a retrospective study
by: Meiqin Zhu, et al.
Published: (2024-12-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
by: Chaoneng He, et al.
Published: (2024-01-01)